Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man.
Open Access
- 1 May 1988
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 25 (5) , 591-598
- https://doi.org/10.1111/j.1365-2125.1988.tb03350.x
Abstract
1. A stereospecific h.p.l.c. assay of nicoumalone in plasma has been developed. 2. The assay was applied to a study in which 20 mg racemic nicoumalone was given orally to three volunteers and blood samples taken for 168 h. 3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R- enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S- enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S- enantiomer. 4. The data are consistent with a substantial first-pass hepatic loss of S-nicoumalone.This publication has 6 references indexed in Scilit:
- Stereospecific Fluorescence High-Performance Liquid Chromatographic Analysis of Warfarin and its Metabolites in Plasma and UrineJournal of Pharmaceutical Sciences, 1984
- Phenylbutazone‐warfarin interaction in man: further stereochemical and metabolic considerations.British Journal of Clinical Pharmacology, 1983
- Pharmacokinetics of the enantiomers of acenocoumarol in man.British Journal of Clinical Pharmacology, 1981
- Effect of Altered Plasma Protein Binding on Apparent Volume of DistributionJournal of Pharmaceutical Sciences, 1979
- Biotransformation and pharmacokinetics of acenocoumarol (Sintrom®) in manEuropean Journal of Clinical Pharmacology, 1977
- Influence of First-Pass Effect on Availability of Drugs on Oral AdministrationJournal of Pharmaceutical Sciences, 1971